PAOG Building CBD Pharma Capacity in Partnership with PURA – Partnership Includes PAOG Stock Dividend to PURA Shareholders

0
28

Sandusky, Ohio–(Newsfile Corp. – November 12, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today confirmed a pharmaceutical and neurocritical extraction partnership with Puration, Inc. (OTC Pink: PURA).

PURA has acquired a 72-acre property in Farmersville, Texas as the foundation of an innovative, hemp processing plant. PURA is building partnerships to participate in the project to include a pharmaceutical and neurocritical extraction partnership with PAOG.

PURA has also established a co-packing partnership with Alkame Holdings, Inc. (OTC Pink: ALKM).

Earlier this week, PURA published a multimedia presentation on the new initiative in Texas:

PURA Targets Hemp Consumer Advocates To Capture $26 Billion Market

PAOG acquired a cannabis cultivation operation from PURA earlier this year in a transaction that includes issuing PAOG shares to PURA shareholders. The target distribution ratio calls for PURA shareholders receiving one share of PAOG for every one share of PURA owned.

For more information on PAO Group, visit www.paogroupinc.com.

Sign up to receive the latest updates at www.purationinc.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

PAO Group, Inc.
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68076

LEAVE A REPLY

Please enter your comment!
Please enter your name here